Strategies for CV Risk Reduction in Complex T2D Patients

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Strategies for CV Risk Reduction in Complex T2D Patients



ReachMD Healthcare Image

Considerations clinicians should be aware of for patients who have both type 2 diabetes and a history of ASCVD. Dive in.

  • Sponsored by

  • Overview

    Managing type 2 diabetes following a cardiovascular event can pose significant challenges for patients. Fortunately, with a combination of medication and lifestyle modifications, patients can reduce their risk of further cardiovascular events. To learn more, join Dr Jennifer Caudle as she speaks with Dr Yehuda Handelsman, Medical Director and Principal Investigator at The Metabolic Institute of America in Tarzana, California, and Dr Michael Blaha, Professor of Cardiology and Epidemiology, as well as Director of Clinical Research at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, Maryland.

    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2023 Novo Nordisk All rights reserved.
    US23DI00110 September 2023

Schedule12 Apr 2024